Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 11, pp 56–64 | Cite as

Lungenkarzinom

Strahlentherapie bei limitierter Metastasierung

  • Daniel SchanneEmail author
  • Nicolaus Andratschke
zertifizierte fortbildung
  • 21 Downloads

Zusammenfassung

In den letzten Jahren hat gerade in der Therapie des Lungenkarzinoms das Konzept der Oligometastasierung an Bedeutung gewonnen. Lesen Sie in der folgenden Übersicht, was darunter zu verstehen ist, welche Formen unterschieden werden und wie sich mittels radiotherapeutischer Verfahren limitiert metastasierte Tumoren (der Lunge) behandeln lassen.

Literatur

  1. 1.
    Stewart BW, Wild CP (Hrsg.), International Agency for Research on Cancer. World Cancer Report 2014. Lyon: IARC Press; 2014Google Scholar
  2. 2.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). https://tinyurl.com/SEER-NSCLC; abgerufen am 2. Oktober 2019
  3. 3.
    Yun YH et al. Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2125–30CrossRefGoogle Scholar
  4. 4.
    Gesellschaft der epidemiologischen Krebsregister e. V. (GEKID) und des Zentrums für Krebsregisterdaten (ZfKD) im Robert Koch-Institut. Krebs in Deutschland für 2013/2014. 2017; https://tinyurl.com/GEKID-Lung; abgerufen am 2. Oktober 2019
  5. 5.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10CrossRefGoogle Scholar
  6. 6.
    Hellman S, Weichselbaum RR. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82CrossRefGoogle Scholar
  7. 7.
    Ashworth A et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197–203CrossRefGoogle Scholar
  8. 8.
    Brierley JD, Gospodarowicz MK, Wittekind C (editors). TNM classification of malignant tumours. 8th ed. Chichester, West Sussex, UK; Hoboken, New Jersey, USA: John Wiley & Sons, Inc; 2017Google Scholar
  9. 9.
    Planchard D et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–iv237CrossRefGoogle Scholar
  10. 10.
    Ettinger DS et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–21CrossRefGoogle Scholar
  11. 11.
    Tree AC et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–37CrossRefGoogle Scholar
  12. 12.
    Palma DA et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–57CrossRefGoogle Scholar
  13. 13.
    Bonnette P et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001;119(5):1469–75CrossRefGoogle Scholar
  14. 14.
    Porte H et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg. 2001;71(3):981–5CrossRefGoogle Scholar
  15. 15.
    Wroński M et al. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg. 1995;83(4):605–16CrossRefGoogle Scholar
  16. 16.
    Rossi NP et al. A combined surgical approach to non-oat-cell pulmonary carcinoma with single cerebral metastasis. Respiration. 1987;51(3):170–8CrossRefGoogle Scholar
  17. 17.
    Palma DA et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816CrossRefGoogle Scholar
  18. 18.
    Iyengar P et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4(1):e173501CrossRefGoogle Scholar
  19. 19.
    Gomez DR et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82CrossRefGoogle Scholar
  20. 20.
    Fleckenstein J et al. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer. 2016;16:348CrossRefGoogle Scholar
  21. 21.
    Weiss J et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019;19:100126CrossRefGoogle Scholar
  22. 22.
    Lax I et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33(6):677–83CrossRefGoogle Scholar
  23. 23.
    Wulf J et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60(1):186–96CrossRefGoogle Scholar
  24. 24.
    Herfarth KK et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164–70CrossRefGoogle Scholar
  25. 25.
    Uematsu M et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51(3):666–70CrossRefGoogle Scholar
  26. 26.
    Kocher M et al. Adjuvant Whole Brain Radiotherapy vs. Observation after Radiosurgery or Surgical Resection of 1–3 Cerebral Metastases - Results of the EORTC 22952-26001 Study. 2009;75(Suppl_3):S5Google Scholar
  27. 27.
    Lodeweges JE et al. Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases. J Thorac Oncol. 2017;12 (9):1442-5Google Scholar
  28. 28.
    Rieber J et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group „stereotactic radiotherapy“. Lung Cancer. 2016;97:51–8CrossRefGoogle Scholar
  29. 29.
    Andratschke N et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Radio-OnkologieUniversitätsspital ZürichZürichSchweiz

Personalised recommendations